Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Metformin for Antipsychotic-Induced Weight Gain in Adults with Intellectual Disability
EF 2023-24
Résumé
Close to 50% of adults with intellectual disability (ID) are overweight or obese. One third of patients with ID are prescribed antipsychotic medications, which are known to cause significant weight gain, leading to obesity and other related diseases, like diabetes. Weight gain is associated with poorer quality of life, decreased social engagement, worse medication adherence, and poorer brain function. Unfortunately, current treatments for managing obesity, and other related risk factors for heart disease, are inadequately studied in individuals with ID. Research has shown that the drug metformin helps to reduce the weight gain associated with antipsychotic drugs, but this has not yet been tested in adults with ID. Our early findings show that metformin may be quite effective in reducing the weight gain associated with taking antipsychotic medication in adults with ID. We plan to study patients with ID who are overweight or obese and are taking antipsychotic medication to test metformin’s ability to reduce body weight and improve heart health. Participants will be randomly assigned to take either metformin or a placebo for 6 months. Neither patients nor study personnel will know if placebo or metformin is being given. All participants will receive diet and lifestyle advice, and have their weight, blood pressure, and waist circumference measured at each visit. We believe that the patients taking metformin will lose a greater percentage of body weight than those who were given the placebo, leading to improvements in heart disease risk factors, physical health and quality of life.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505840
Name
Ahmed Tariq B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metformin for Antipsychotic-Induced Weight Gain in Adults with Intellectual Disability
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adults; Antipsychotic-Induced Weight Gain; Intellectual Disability; Metabolic Syndrome; Metformin; Obesity; Physical Health; Randomized Control Trial
Abstract
Close to 50% of adults with intellectual disability (ID) are overweight or obese. One third of patients with ID are prescribed antipsychotic medications, which are known to cause significant weight gain, leading to obesity and other related diseases, like diabetes. Weight gain is associated with poorer quality of life, decreased social engagement, worse medication adherence, and poorer brain function. Unfortunately, current treatments for managing obesity, and other related risk factors for heart disease, are inadequately studied in individuals with ID. Research has shown that the drug metformin helps to reduce the weight gain associated with antipsychotic drugs, but this has not yet been tested in adults with ID. Our early findings show that metformin may be quite effective in reducing the weight gain associated with taking antipsychotic medication in adults with ID. We plan to study patients with ID who are overweight or obese and are taking antipsychotic medication to test metformin’s ability to reduce body weight and improve heart health. Participants will be randomly assigned to take either metformin or a placebo for 6 months. Neither patients nor study personnel will know if placebo or metformin is being given. All participants will receive diet and lifestyle advice, and have their weight, blood pressure, and waist circumference measured at each visit. We believe that the patients taking metformin will lose a greater percentage of body weight than those who were given the placebo, leading to improvements in heart disease risk factors, physical health and quality of life.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ahmed, Tariq B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~